DIAGNOSTIC TEST 018

Autoimmune Liver Disease Screen

Diagnostic test for LKM-1, LC-1, AMA-M2, M2-3E (BPO), Sp100, PML, gp210, SLA/LP, and Ro-52. For suspicion of autoimmune liver disease.

Indication

Suspicion of autoimmune liver disease

Sample material

Serum

  • Minim. volume: 0,5 mL

Transport

  • Within Sweden: room temperature
  • International: cold

Method

Immunoblot

Reference interval

<11 negative

Result

Results are reported as negative or positive with reaction intensity.

Interpretation

  • Antibodies against mitochondrial (AMA) type M2 are a marker for manifest or future development of primary biliary cholangitis (PBC) and occur in just over 90% of the cases. In PBC, a strongly positive reaction for AMA-M2 is usually detected. Weakly positive findings that cannot be verified by an alternative method are interpreted as lacking clinical significance. In cases of overlapping PBC/autoimmune hepatitis (AIH), AIH markers can occur simultaneously with AMA-M2.
  • M2-3E (BPO) is a recombinant fusion protein composed of various subunits of the mitochondrial antigen M2. Antibodies against mitochondria (AMA) type M2 are markers for manifest or future development of primary biliary cholangitis (PBC) and occur in just over 90% of the cases. In PBC, a strongly positive reaction for AMA-M2 is usually detected. Weakly positive findings that cannot be verified by an alternative method are interpreted as lacking clinical significance. In overlapping PBC/autoimmune hepatitis (AIH), AIH markers may occur simultaneously with AMA-M2.
  • Antibodies against Sp100 are a strong marker for PBC (primary biliary cholangitis) and can occur with or without the simultaneous presence of AMA-M2.
  • Antibodies against PML can in rare cases be seen in PBC (primary biliary cholangitis) but rarely occur in isolation.
  • Antibodies against gp210 are a strong marker for PBC (primary biliary cholangitis) and are associated with a more aggressive disease course.
  • Antibodies against LKM-1 are a marker for autoimmune hepatitis (AIH).
  • Antibodies against LC-1 most often occur together with LKM-1 antibodies and are a marker for autoimmune hepatitis (AIH). Isolated occurrence of anti-LC1 occurs in about 10% of the cases. The value of a weakly positive reaction is uncertain. Strongly positive anti-LC1 is associated with a more severe disease course. Anti-LC-1 has in rare cases been reported in hepatitis C.
  • Antibodies to SLA/LP are a strong marker for autoimmune hepatitis (AIH) and are present in approximately 10% of the cases. Anti-SLA is associated with a more severe course of the disease and can occur without ANA and/or smooth muscle antibodies being detected.
  • Anti-SSA/Ro52 is associated with several different autoimmune conditions such as autoimmune liver disease, anti-synthetase syndrome and other inflammatory systemic diseases.

References

  • European Association for the Study of the Liver. J Hepatol. 2025. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. PMID: 40348684.
  • Bonroy C et al. Clin Chem Lab Med. 2023 Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP. Clin Chem Lab Med. 2023 PMID: 36989417.
  • Chan EKL et al. LEC; ICAP Committee. The International Consensus on ANA Patterns (ICAP) in 2021-The 6th Workshop and Current Perspectives. J Appl Lab Med. 2022 Jan 5;7(1):322-330. PMID: 34996073.
  • Terziroli Beretta-Piccoli B et al. J Autoimmun. 2018. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview.
  • Hennes EM et al. Hepatology. 2008. Simplified criteria for the diagnosis of autoimmune hepatitis. PMID: 18537184.

Included in these panels

Need pricing information?

Get a quote

How to order

This test is available worldwide for hospitals, clinics, and physicians.

  1. Print and complete the request form

    Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. If you are a new customer, please also include a completed customer information form.

  2. Prepare your samples

    Serum: At least 0.5 mL serum (plain serum tubes without additives).

  3. Send samples and request form

    Within Sweden
    Samples can be sent at room temperature to:
    Envelopes and smaller boxes:
    Wieslab AB, Box 50117, 20211 Malmö, Sweden

    Larger boxes and frozen samples:
    Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden

    International
    Send samples cold to:
    Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden

Last updated: 2026-08-13